COVID-19 y dolor crónico: muchos interrogantes y pocas certezas

Estudio descriptivo sobre el perfil de los pacientes derivados a la Unidad de Tratamiento del Dolor Crónico del Hospital Universitario de Gran Canaria Dr. Negrín (UTDC-HUGCDN) como base para la reorganización de esta

“…Destacar la caída de derivaciones en relación con las "oleadas" de COVID-19 y su evolución; así en la primera oleada constatamos un descenso de alrededor de 60 pacientes al mes durante 3 meses, en la segunda de unos 40 pacientes al mes durante 2 meses y en la tercera poco más de 20 y durante un solo mes (cifra no incluida en este estudio por ser recogida a posteriori). Esto nos puede indicar que hay una adaptación progresiva que tiende a normalizar la actividad asistencial con el paso del tiempo, tras el impacto inicial ya documentado en varios estudios 1,2 , amoldándonos a esta nueva realidad y tendiendo a minimizar el impacto de la COVID-19 en la asistencia sanitaria.…”

Depression and COVID-19 patients with chronic pain: practical considerations

“…We also reflect on whether the stress caused by this situation, the anxiety, and even the resulting depression negatively contribute by closing this vicious circle, which undoubtedly is the case [ 5 ]. In fact, patients with chronic pain who must, just like any other citizen, be in isolation or observe social distancing due to the COVID-19 pandemic may experience a decline in their physical and emotional well-being [ 6 ].…”

“…For example, amitriptyline and venlafaxine may cause QTc interval prolongation, but currently, evidence is lacking on any risk of Torsades de Pointes when they are administered at the recommended dose. For this reason, we recommend monitoring using an electrocardiogram in the event of a combination or considering an alternative such as duloxetine [ 6 ]. It is also necessary to be aware of the possible interactions of these analgesic and adjuvant drugs with the pharmacological treatment applied to patients who are COVID-19 positive and affected by the illness.…”

“…It is also necessary to be aware of the possible interactions of these analgesic and adjuvant drugs with the pharmacological treatment applied to patients who are COVID-19 positive and affected by the illness. With regard to the latter, while these clinical and therapeutic dilemmas are resolved, specific information can be found on these medical interactions at trustworthy sites, such as https://www.hep-druginteractions.org/checker [ 6 ].…”

Cost analysis of chronic pain due to musculoskeletal disorders in Chile

“…Furthermore, MSKD is one of the leading causes of disease burden, accounting for 139 million disability-adjusted life years (DALYs) [ 5 ]. The COVID-19 pandemic has worsened these people’s pain, expecting that this problem’s magnitude will continue to grow even more than the pre-pandemic indicators [ 6 , 7 ].…”